Skip to main content

Advertisement

SpringerLink
Log in

Direct renin inhibitors: ONTARGET for success?

  • Nephrology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Direct renin inhibitors are the first new class of antihypertensive to emerge since angiotensin II receptor blockers. We discuss their reno- and cardioprotective potential, based on extrapolation from animal models and phase three trials that are currently ongoing. This paper reviews the potential benefits of direct renin inhibitors (DRIs), the only new anti-hypertensive class developed in the last decade, as compared to pre-existing classes of drug inhibiting more downstream, such as Angiotensin Converting Enzyme inhibitors (ACEI), Angiotensin 2 Receptor Blockers (ARBS).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Yusuf S, Teo K, Porge J et al (2008) Telmisartan, ramipril or both in patients at high risk for vascular events (ONTARGET Trial) NEJM 358:1547–1159

    Google Scholar 

  2. Mann JF, Schmieder RE, McQueen M et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553

    Article  PubMed  CAS  Google Scholar 

  3. Dalla Vestra M, Simioni N, Masiero A (2009) Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy. Int Urol Nephrol 41:119–126

    Article  PubMed  CAS  Google Scholar 

  4. Casas JP, Chua W, Loukogeorgakis S et al (2005) Effect of inhibitors of the renin angiotensin system and other antihypertensive drugs on renal outcomes; systematic review and meta-analysis. Lancet 366:2026–2033

    Article  PubMed  CAS  Google Scholar 

  5. Sarafidis P, Khosla N, Bakri GL (2007) Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49:12–26

    Article  PubMed  CAS  Google Scholar 

  6. Covic A, Gusbeth-Tatomir P, Goldsmith DJA (2007) Current dilemmas in inhibiting the renin-angiotensin system: do not forget real life. Int Urol Nephrol 39:571–576

    Article  PubMed  Google Scholar 

  7. Bakris GL (2004) Clinical Importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep 6:352–356

    Article  PubMed  Google Scholar 

  8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. Study Investigators. N Engl J Med 342:145–153

    Article  PubMed  CAS  Google Scholar 

  9. Ibsen H, Olsen MH, Wachtell K et al (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198–202

    Article  PubMed  CAS  Google Scholar 

  10. Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860

    Article  PubMed  CAS  Google Scholar 

  11. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF (1993) Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med 118:129–138

    PubMed  CAS  Google Scholar 

  12. Barnett AH (2005) Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol 42(Suppl 1):S42–S49

    Article  PubMed  CAS  Google Scholar 

  13. Estacio RO, Jeffers BW, Gifford N, Schrier RW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2):B54–B64

    PubMed  Google Scholar 

  14. Karalliedde J, Viberti G (2006) Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 20:239–253

    Article  PubMed  CAS  Google Scholar 

  15. Jafar TH, Schmid CH, Landa M et al for the ACE inhibition in progressive renal disease study group (2001) Angiotensin converting enzyme inhibitors and progression of non diabetic renal disease: a meta-analysis of patient level data. Ann Intern Med 135:73–87

    Google Scholar 

  16. The GISEN Group (1997) Randomised placebo-controlled trial of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuria, non diabetic nephropathy. Lancet 349:1857–1863

    Google Scholar 

  17. Wright JT Jr, Bakris G, Green T et al for the American study of Kidney disease, Hypertension Study Group (2002) Effect of Blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease; results from the AASK trial. JAMA 228:2421–2431

    Google Scholar 

  18. Monster TBM, Janssen WMT, de Jong PE, den Berg LTG, for the PREVEND Study Group (2002) The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population. Br J Clin Pharmacol 53:31–36

    Google Scholar 

  19. Sugino G, Barg AP, O’Connor ST (1984) Renal perfusion is preserved during cardioselective beta blockade with metoprolol in hypertension. Am J Kidney Dis 3:357–361

    PubMed  CAS  Google Scholar 

  20. Tindall H, Urquhart S, Stickland M et al (1991) Treatment with atenolol prevents progression of microalbuminuria in type 1 diabetic patients. Curr Med Res Opin 12:516–520

    PubMed  CAS  Google Scholar 

  21. Nyugen G, Delarue F, Burckle C et al (2002) Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 10:1417–1427

    Google Scholar 

  22. Brunner HR, Nussberger J, Weber B (1990) Various approaches to blockade of renin-angiotensin system: persistent renin response. J Hypertens 8(7):S149–S153

    CAS  Google Scholar 

  23. Hollenberg NK, Fisher ND, Price DA (1998) Pathways for angiotensin II generation in intact human tissue; evidence from comparative pharmacological interruption of the renin system. Hypertension 32:387–392

    PubMed  CAS  Google Scholar 

  24. Hollenberg NK, Fisher NDL (1995) Renal circulation and blockade of the renin-angiotensin system. Hypertension 26:602–609

    PubMed  CAS  Google Scholar 

  25. Wolf G, Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67:799–812

    Article  PubMed  CAS  Google Scholar 

  26. Van der Wal RM, Plokker HW, Lok DJ et al (2006) Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 106:367–372

    Article  PubMed  Google Scholar 

  27. Blasi ER, Rocha R, Rudolph AE et al (2003) Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63:1791–1800

    Article  PubMed  CAS  Google Scholar 

  28. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL (2004) Involvement of oxidative stress in the profibrotic action of aldosterone; interaction with the renin angiotensin system. Am J Hypertens 17:597–603

    PubMed  CAS  Google Scholar 

  29. Athyros VG, Mikhailides DP, Kakafika AI, Tziomalos K, Karagiannis A (2007) Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 8:529–535

    Article  PubMed  CAS  Google Scholar 

  30. Brunner HR, Laragh JH, Baer L et al (1972) Essential hypertension, renin, aldosterone, heart attacks, strokes. N Engl J Med 286:441–449

    PubMed  CAS  Google Scholar 

  31. Villamil A, Chrysant SG, Calhoun D et al (2007) Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25:217–225

    Article  PubMed  CAS  Google Scholar 

  32. Azizi M, Menard J, Bissery A, Bura-Riviere A, Vaidyanathan S, Camisasca RP (2004) Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15:3126–3133

    Article  PubMed  Google Scholar 

  33. Kilo C, Taylor A, Tschoepe D (2006) Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes. Eur Heart J 25(Suppl):118 [Abstract P789]

    Google Scholar 

  34. Pool J, Gradman A, Kolloch R (2006) Aliskiren, a novel renin inhibitor, provides long term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. Eur Heart J 25(Suppl):119 [Abstract P790]

    Google Scholar 

  35. Mitchell J, Oh B, Herron J et al (2006) Once daily aliskiren provides effective smooth 24 hour blood pressure control in patients with hypertension. J Clin Hypertens 8 (Suppl A):A93(P-209)

  36. Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II suppression in humans by orally active renin inhibitor aliskiren (SP100): comparison with enalapril. Hypertension 39:E1–E8

    Article  PubMed  CAS  Google Scholar 

  37. Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24:243–256

    Article  PubMed  CAS  Google Scholar 

  38. Tekturna (aliskiren) prescribing information. Available at http://www.fda.gov

  39. Dieterle W, Corynen S, Vaidyanathan S et al (2005) Pharmacokinetic interactions of oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 43:527–535

    PubMed  CAS  Google Scholar 

  40. Dieterle W, Corynen S, Mann J (2004) Effect of oral renin inhibitor aliskiren, on pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Pharmacol 58:433–436

    Article  Google Scholar 

  41. Pilz B, Shagdarsuren E, Wellner M et al (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46:569–576

    Article  PubMed  CAS  Google Scholar 

  42. Cheng H, Harris RC (2006) Potential side effects of renin inhibitors-mechanisms based on comparison with other renin-angiotensin blockers. Expert Opin Drug Saf 5:631–641

    Article  PubMed  CAS  Google Scholar 

  43. Cordero P, Fisher ND, Moore TJ et al (1991) Renal and endocrine responses to a renin inhibitor enalkiren, in normal humans. Hypertension 17:510–516

    PubMed  CAS  Google Scholar 

  44. Fisher NDL, Allan D, Kifor I et al (1994) Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension 23:44–51

    PubMed  CAS  Google Scholar 

  45. Fisher NDL, Hollenberg NK (1995) Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther 57:342–348

    Article  PubMed  CAS  Google Scholar 

  46. El-Amrani A-IK, Menard J, Gonzales MF, Michel JB (1993) Effects of blocking the angiotensin II receptor, converting enzyme and renin activity on the renal hemodynamics of normotensive guinea pigs. J Cardiovasc Pharmacol 22:231–239

    Article  PubMed  CAS  Google Scholar 

  47. Fisher NDL, Allan DR, Gaboury CL, Hollenberg NK (1995) Intrarenal angiotensin II formation in humans. Evidence from renin inhibition. Hypertension 25:935–939

    PubMed  CAS  Google Scholar 

  48. Feldman DL, Persohn E, Schutz H et al (2006) Renal localisation of the renin inhibitor aliskiren. J Clin Hypertens 8(Suppl A):A80

    Google Scholar 

  49. Kapoor S (2008) Aliskiren: a rapidly, expanding role in the management of recalcitrant hypertension and renal disease. Int Urol Nephrol 40(4):1115–1116

    Google Scholar 

  50. Siamopoulos KC, Kalaitzidis RG (2008) Inhibition of the renin-angiotensin system and chronic kidney disease. Int Urol Nephrol 40:1015–1025

    Article  PubMed  CAS  Google Scholar 

  51. Recio-Mayoral A, Kaski JC, McMurray JJ et al (2007) Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc Drugs Ther 21(6):459–465

    Google Scholar 

  52. Oh BH, Mitchell J, Herron JR et al (2007) Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49:1157–1163

    Article  PubMed  CAS  Google Scholar 

  53. Weir M, Bush C, Zhang J, Keefe D, Satlin A (2006) Antihypertensive efficacy and benefits of oral renin inhibitor aliskiren in patients with hypertension. A pooled analysis. Eur Heart J 27(Suppl):299 [Abstract 1796]

    Google Scholar 

  54. Segall L, Covic A, Goldsmith DJA (2007) Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol Dial Transplant 22:2435–2439

    Article  PubMed  Google Scholar 

  55. Nakao N, Yoshimura A, Morita H et al (2003) Combination treatment of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised control trial. Lancet 361:117–124

    Article  PubMed  CAS  Google Scholar 

  56. Campbell R, Sangalli F, Pertucci E et al (2003) Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chorionic nephropathies. Kidney Int 63:1094–1103

    Article  PubMed  CAS  Google Scholar 

  57. Krum H, Gilbert E (2007) Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J Hypertens 25:25–35

    Article  PubMed  CAS  Google Scholar 

  58. Munger MA, Drummond W, Essop MR (2006) Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur Heart J 25(Suppl):117 [Abstract: P784]

    Google Scholar 

  59. Stanton A, Jensen C, Nussberger J, O’Brien E (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42:1137–1143

    Article  PubMed  CAS  Google Scholar 

  60. Gradman A, Schmieder RE, Lins RL et al (2005) Aliskiren, a novel orally effective renin inhibitor, provides dose dependent antihypertensive efficacy and placebo like tolerability in hypertensive patients. Circulation 111:1012–1018

    Article  PubMed  CAS  Google Scholar 

  61. Pool JL, Schmeider RE, Azizi M et al (2007) Aliskiren an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 20:11–20

    Article  PubMed  CAS  Google Scholar 

  62. Clozel JP, Véniant MM, Qiu C, Sprecher U, Wolfgang R, Fischli W (1999) Renal vascular and biochemical responses to systemic renin inhibition in dogs at low renal perfusion pressure. J Cardiovasc Pharmacol 34:674–682

    Article  PubMed  CAS  Google Scholar 

  63. Van Paasen P, de Zeeuw D, Navis G, de Jong PE (2000) Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 15:637–643

    Article  Google Scholar 

  64. Parving HH, Persson F, Lewis JB et al (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433–2446

    Article  PubMed  CAS  Google Scholar 

  65. Persson F, Rossing P, Schjoedt KJ et al (2008) Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 73:1419–1425

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

Dres. Goldsmith and Covic received honoraria and speaker fees from Novartis.

Author information

Authors and Affiliations

  1. Chelsea and Westminster Hospital, Fulham Road, London, UK

    Yasmin Pasha

  2. Nephrology Clinic, Parhon University Hospital, “Gr.T. Popa” University of Medicine and Pharmacy, Iasi, Romania

    Paul Gusbeth-Tatomir & Adrian Covic

  3. Renal Unit, Guy’s Hospital, London, UK

    David Goldsmith

Authors
  1. Yasmin Pasha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Gusbeth-Tatomir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adrian Covic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Goldsmith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Gusbeth-Tatomir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pasha, Y., Gusbeth-Tatomir, P., Covic, A. et al. Direct renin inhibitors: ONTARGET for success?. Int Urol Nephrol 41, 341–355 (2009). https://doi.org/10.1007/s11255-009-9556-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-009-9556-7

Keywords

Search

Navigation